S&P 500   3,308.06 (+1.13%)
DOW   26,643.65 (+0.47%)
QQQ   275.97 (+1.59%)
AAPL   115.13 (+3.53%)
MSFT   204.74 (+1.02%)
FB   281.46 (+5.15%)
GOOGL   1,560.36 (+3.28%)
AMZN   3,217.14 (+1.72%)
TSLA   413.18 (+1.76%)
NVDA   522.09 (+3.37%)
BABA   309.91 (+0.64%)
CGC   18.35 (+0.05%)
GE   7.32 (-1.35%)
MU   50.32 (+0.64%)
AMD   78.48 (+2.72%)
T   26.69 (+0.72%)
F   7.86 (+2.08%)
ACB   3.83 (+0.00%)
GILD   57.57 (-1.96%)
NFLX   484.39 (-0.38%)
NIO   30.85 (+12.14%)
BA   146.67 (-0.99%)
DIS   119.97 (+1.27%)
S&P 500   3,308.06 (+1.13%)
DOW   26,643.65 (+0.47%)
QQQ   275.97 (+1.59%)
AAPL   115.13 (+3.53%)
MSFT   204.74 (+1.02%)
FB   281.46 (+5.15%)
GOOGL   1,560.36 (+3.28%)
AMZN   3,217.14 (+1.72%)
TSLA   413.18 (+1.76%)
NVDA   522.09 (+3.37%)
BABA   309.91 (+0.64%)
CGC   18.35 (+0.05%)
GE   7.32 (-1.35%)
MU   50.32 (+0.64%)
AMD   78.48 (+2.72%)
T   26.69 (+0.72%)
F   7.86 (+2.08%)
ACB   3.83 (+0.00%)
GILD   57.57 (-1.96%)
NFLX   484.39 (-0.38%)
NIO   30.85 (+12.14%)
BA   146.67 (-0.99%)
DIS   119.97 (+1.27%)
S&P 500   3,308.06 (+1.13%)
DOW   26,643.65 (+0.47%)
QQQ   275.97 (+1.59%)
AAPL   115.13 (+3.53%)
MSFT   204.74 (+1.02%)
FB   281.46 (+5.15%)
GOOGL   1,560.36 (+3.28%)
AMZN   3,217.14 (+1.72%)
TSLA   413.18 (+1.76%)
NVDA   522.09 (+3.37%)
BABA   309.91 (+0.64%)
CGC   18.35 (+0.05%)
GE   7.32 (-1.35%)
MU   50.32 (+0.64%)
AMD   78.48 (+2.72%)
T   26.69 (+0.72%)
F   7.86 (+2.08%)
ACB   3.83 (+0.00%)
GILD   57.57 (-1.96%)
NFLX   484.39 (-0.38%)
NIO   30.85 (+12.14%)
BA   146.67 (-0.99%)
DIS   119.97 (+1.27%)
S&P 500   3,308.06 (+1.13%)
DOW   26,643.65 (+0.47%)
QQQ   275.97 (+1.59%)
AAPL   115.13 (+3.53%)
MSFT   204.74 (+1.02%)
FB   281.46 (+5.15%)
GOOGL   1,560.36 (+3.28%)
AMZN   3,217.14 (+1.72%)
TSLA   413.18 (+1.76%)
NVDA   522.09 (+3.37%)
BABA   309.91 (+0.64%)
CGC   18.35 (+0.05%)
GE   7.32 (-1.35%)
MU   50.32 (+0.64%)
AMD   78.48 (+2.72%)
T   26.69 (+0.72%)
F   7.86 (+2.08%)
ACB   3.83 (+0.00%)
GILD   57.57 (-1.96%)
NFLX   484.39 (-0.38%)
NIO   30.85 (+12.14%)
BA   146.67 (-0.99%)
DIS   119.97 (+1.27%)
Log in
NYSE:IBIO

iBio Stock Forecast, Price & News

$1.79
-0.05 (-2.72 %)
(As of 10/29/2020 01:16 PM ET)
Add
Compare
Today's Range
$1.76
Now: $1.79
$1.83
50-Day Range N/A
52-Week Range
$0.05
Now: $1.79
$7.45
Volume54,987 shs
Average Volume23.24 million shs
Market Capitalization$322.72 million
P/E RatioN/A
Dividend YieldN/A
Beta-5.88
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone302-355-0650
Employees55

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.64 million
Book Value$0.48 per share

Profitability

Net Income$-16,440,000.00
Net Margins-1,003.60%

Miscellaneous

Market Cap$322.72 million
Next Earnings DateN/A
OptionableOptionable
$1.79
-0.05 (-2.72 %)
(As of 10/29/2020 01:16 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











iBio (NYSE:IBIO) Frequently Asked Questions

Who are some of iBio's key competitors?

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Sorrento Therapeutics (SRNE), Tesla (TSLA), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arista Networks (ANET), Aquestive Therapeutics (AQST), Alphatec (ATEC), Alibaba Group (BABA), Boxlight (BOXL) and Ford Motor (F).

Who are iBio's key executives?

iBio's management team includes the following people:
  • Mr. Thomas F. Isett III, CEO & Chairman (Age 55, Pay $30k)
  • Mr. Robert L. Erwin, Pres (Age 67, Pay $275k)
  • Dr. Renato Lobo, Chief Medical Officer
  • Dr. R. Barry Holtz, Pres of iBio CDMO
  • Carlos Picosse, Chief Exec. Officer of IBio Brazil

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE) under the ticker symbol "IBIO."

How do I buy shares of iBio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $1.80.

How big of a company is iBio?

iBio has a market capitalization of $323.62 million and generates $1.64 million in revenue each year. iBio employs 55 workers across the globe.

What is iBio's official website?

The official website for iBio is www.ibioinc.com.

How can I contact iBio?

iBio's mailing address is 600 Madison Avenue Suite 1601, New York NY, 10022. The company can be reached via phone at 302-355-0650 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.